Role of Astrocyte EAAT2/GLT1 Failure in Alzheimer's Disease Pathogenesis
星形胶质细胞 EAAT2/GLT1 故障在阿尔茨海默病发病机制中的作用
基本信息
- 批准号:10343484
- 负责人:
- 金额:$ 79.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenovirus VectorAffectAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease patientAmyloidAmyloid beta-42AnabolismAnatomyAstrocytesAutomobile DrivingAutopsyBackBindingBrainBrain PathologyBrain regionCellsComplementDataDependovirusDiseaseDysmorphologyElectrophysiology (science)EquilibriumExtracellular SpaceFailureFamilyFunctional disorderGene ExpressionGeneticGlial Fibrillary Acidic ProteinGlutamate TransporterGlutamatesGlutamineGoalsHippocampus (Brain)HomeostasisImpaired cognitionInterneuronsInterventionKnowledgeLentivirusLentivirus VectorMeasuresMediatingMemoryMetabolicMethodsMolecular TargetMorphologyMusNeuronsNeurotransmittersOccupationsPathogenesisPathogenicityPathologyPathway interactionsPlayPositioning AttributeProcessPropertyProteinsPublishingPyramidal CellsRecoveryReportingResearchRoleSliceSpecificitySynapsesSynaptic TransmissionSystemTestingToxic effectWorkastrogliosiscognitive functionexcitotoxicityextracellulargamma-Aminobutyric Acidin vivoinsightmild cognitive impairmentmind controlmouse modelneuron lossneuropathologyneurotoxicneurotransmissionnovelpatch clamppreventprodromal Alzheimer&aposs diseaseresponsesingle-cell RNA sequencingsynergismtau Proteinstau expressiontau-1transcriptomicstranslational potentialtransmission processuptake
项目摘要
Astrocytes are ideally positioned to support neuronal/synaptic needs for trophic factors, metabolic
homeostasis, and protection from toxicity. While reactive astrogliosis is a prominent feature of AD, this offers
very limited insight about how astrocytes influence the disease process or how they may be harmed.
One of the most important functions of astrocytes is to clear extracellular glutamate to prevent excitotoxicity.
Glutamate taken up by astrocytes is also used as a metabolic substrate for biosynthesis of other neuro-
transmitters like GABA. Thus, there are at least two major ways astrocytic glutamate clearance protects the
brain. In cortex and hippocampus, the glutamate transporter Slc1a2 (also called GLT1 or EAAT2) plays the
most important role in glutamate clearance. Most, but not all Slc1a2 is in astrocytes.
Our research team has shown that: (i) Slc1a2 is disturbed in AD; (ii) Slc1a2 loss in an AD mouse model
accelerates onset of cognitive impairment; (iii) A42 slows synaptically-released glutamate uptake in hippo-
campal slices; and (iv) mice with reduced astrocytic Slc1a2 display significant transcriptomic overlaps with AD.
These data complement strong work from other groups and collectively argue that Slc1a2 dysfunction may
play an important role in AD. However, additional critical questions need to be answered to better understand
how astrocytic Slc1a2 may interact with A42 and tau pathology. Specifically, is there pathogenic synergy
among these processes? In AD more needs to be uncovered about the relationship between neurons and the
fine (often GFAP-negative) astrocytic processes expressing nearly all Slc1a2 in the brain—an anatomical
relationship that is crucial to their function. In addition, there is insufficient data supporting the hypothesis that
astrocytic Slc1a2 can play a contributing or causal role in exacerbating A42 and tau pathology.
The goal of this project is to fill these knowledge gaps. First, we will use novel mice with reduced Slc1a2
specifically in astrocytes; and with adenoviral vectors (AAVs) expressing A42 and tauP301L, dissect the in
vivo molecular interactions between these pathogenic pathways. We will address whether astrocytes are lost in
response to A42 and/or tau. We will use a novel lentivirus system expressing Slc1a2, which infects astrocytes,
to test whether specifically rescuing astrocytic Slc1a2 ameliorates neuropathology, as well as Slc1a2 function.
Second, using state-of-the art patch clamp methods that directly measure astrocyte glutamate clearance,
dissect how Slc1a2 loss, A42, and tau expression interact to affect astrocytic glutamate clearance. We will
address how these pathogenic processes influence astrocytic Slc1a2 that regulate synaptic network excitability
by supporting GABAergic transmission. Third, using well-characterized postmortem brains from control,
prodromal, and AD patients we will test the potential translational significance of the glutamate transporter and
astrocyte neuropathology we have reported and is suggested by our new preliminary data. Together, these
data hold promise of advancing our knowledge of Slc1a2 as a potential molecular target for intervention in AD.
星形胶质细胞被理想地定位以支持神经元/突触对营养因子、代谢调节因子和神经元/突触的需要。
体内平衡和保护免受毒性。虽然反应性星形胶质细胞增生是AD的突出特征,但这提供了
关于星形胶质细胞如何影响疾病过程或它们如何受到伤害的见解非常有限。
星形胶质细胞最重要的功能之一是清除细胞外谷氨酸以防止兴奋性毒性。
由星形胶质细胞摄取的谷氨酸也用作其他神经细胞生物合成的代谢底物。
像γ-氨基丁酸这样的神经递质因此,至少有两种主要的方式,星形胶质细胞谷氨酸清除保护神经元。
个脑袋在大脑皮层和海马体中,谷氨酸转运蛋白Slc 1a 2(也称为GLT 1或EAAT 2)起着重要的作用。
谷氨酸清除中最重要的作用。大多数,但不是所有的Slc 1a 2是在星形胶质细胞。
我们的研究小组已经表明:(i)Slc 1a 2在AD中受到干扰;(ii)Slc 1a 2在AD小鼠模型中丢失
加速认知障碍的发生;(iii)A 42减缓河马突触释放的谷氨酸吸收,
(iv)星形胶质细胞Slc 1a 2减少的小鼠显示出与AD显著的转录组重叠。
这些数据补充了来自其他小组的强有力的工作,并共同认为Slc 1a 2功能障碍可能
在AD中发挥重要作用。然而,需要回答其他关键问题,以更好地理解
星形胶质细胞Slc 1a 2如何与A β 42和tau病理学相互作用。具体来说,是否存在致病协同作用
在这些过程中?在AD中,需要更多地揭示神经元和神经元之间的关系。
精细(通常为GFAP阴性)星形胶质细胞突起表达大脑中几乎所有Slc 1a 2-解剖学
这对它们的功能至关重要。此外,没有足够的数据支持以下假设:
星形胶质细胞Slc 1a 2可以在加重A β 42和tau病理中起促进或因果作用。
这个项目的目标是填补这些知识空白。首先,我们将使用Slc 1a 2减少的新型小鼠,
特别是在星形胶质细胞中;并与表达A342和tauP 301 L的腺病毒载体(AAV)一起,解剖了星形胶质细胞中的
这些致病途径之间的体内分子相互作用。我们将讨论星形胶质细胞是否在
对A 42和/或tau的反应。我们将使用一种新的表达Slc 1a 2的慢病毒系统,该系统感染星形胶质细胞,
以测试是否专门拯救星形胶质细胞Slc 1a 2改善神经病理学,以及Slc 1a 2功能。
其次,使用最先进的膜片钳方法直接测量星形胶质细胞谷氨酸清除率,
研究Slc 1a 2缺失、A β 42和tau蛋白表达如何相互作用影响星形胶质细胞谷氨酸清除。我们将
阐明这些致病过程如何影响调节突触网络兴奋性的星形胶质细胞Slc 1a 2
通过支持GABA能传输。第三,使用控制组中特征鲜明的死后大脑,
前驱期和AD患者,我们将测试谷氨酸转运蛋白的潜在翻译意义,
星形胶质细胞神经病理学,我们已经报告,并建议由我们的新的初步数据。所有这些
这些数据有望推进我们对Slc 1a 2作为AD干预的潜在分子靶点的认识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David G Cook其他文献
David G Cook的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David G Cook', 18)}}的其他基金
Role of Astrocyte EAAT2/GLT1 Failure in Alzheimer's Disease Pathogenesis
星形胶质细胞 EAAT2/GLT1 故障在阿尔茨海默病发病机制中的作用
- 批准号:
10594014 - 财政年份:2022
- 资助金额:
$ 79.82万 - 项目类别:
Building translationally relevant relationships between neuropathology and abnormal neuroimaging in Veterans and mechanisms of blast-induced neurotrauma in mice
建立退伍军人的神经病理学和异常神经影像以及小鼠爆炸引起的神经创伤机制之间的转化相关关系
- 批准号:
10082417 - 财政年份:2013
- 资助金额:
$ 79.82万 - 项目类别:
The role of glia dysfunction in the neurodegenerative processes induced by blast
神经胶质细胞功能障碍在爆炸引起的神经退行性过程中的作用
- 批准号:
8633554 - 财政年份:2013
- 资助金额:
$ 79.82万 - 项目类别:
The role of glia dysfunction in the neurodegenerative processes induced by blast
神经胶质细胞功能障碍在爆炸引起的神经退行性过程中的作用
- 批准号:
9275411 - 财政年份:2013
- 资助金额:
$ 79.82万 - 项目类别:
Glutamate dyshomeostasis: The role of glutamate transport dysfunction in Alzheim
谷氨酸稳态失调:谷氨酸转运功能障碍在阿尔茨海默病中的作用
- 批准号:
8195897 - 财政年份:2009
- 资助金额:
$ 79.82万 - 项目类别:
Glutamate dyshomeostasis: The role of glutamate transport dysfunction in Alzheim
谷氨酸稳态失调:谷氨酸转运功能障碍在阿尔茨海默病中的作用
- 批准号:
7907841 - 财政年份:2009
- 资助金额:
$ 79.82万 - 项目类别:
Glutamate dyshomeostasis: The role of glutamate transport dysfunction in Alzheim
谷氨酸稳态失调:谷氨酸转运功能障碍在阿尔茨海默病中的作用
- 批准号:
7796986 - 财政年份:2009
- 资助金额:
$ 79.82万 - 项目类别:
Glutamate dyshomeostasis: The role of glutamate transport dysfunction in Alzheim
谷氨酸稳态失调:谷氨酸转运功能障碍在阿尔茨海默病中的作用
- 批准号:
8391149 - 财政年份:2009
- 资助金额:
$ 79.82万 - 项目类别:
Modulation of A-beta production in Alzheimer's disease
阿尔茨海默病中 A-β 产生的调节
- 批准号:
6455084 - 财政年份:2001
- 资助金额:
$ 79.82万 - 项目类别:
Modulation of A-beta production in Alzheimer's disease
阿尔茨海默病中 A-β 产生的调节
- 批准号:
6359540 - 财政年份:2000
- 资助金额:
$ 79.82万 - 项目类别:
相似海外基金
Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
- 批准号:
19K09482 - 财政年份:2019
- 资助金额:
$ 79.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
- 批准号:
2273599 - 财政年份:2019
- 资助金额:
$ 79.82万 - 项目类别:
Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
- 批准号:
18K14964 - 财政年份:2018
- 资助金额:
$ 79.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
- 批准号:
16K18873 - 财政年份:2016
- 资助金额:
$ 79.82万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
- 批准号:
9193681 - 财政年份:2016
- 资助金额:
$ 79.82万 - 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
- 批准号:
15K18939 - 财政年份:2015
- 资助金额:
$ 79.82万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
- 批准号:
26450450 - 财政年份:2014
- 资助金额:
$ 79.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
- 批准号:
26462183 - 财政年份:2014
- 资助金额:
$ 79.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
- 批准号:
26893253 - 财政年份:2014
- 资助金额:
$ 79.82万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
- 批准号:
24701021 - 财政年份:2012
- 资助金额:
$ 79.82万 - 项目类别:
Grant-in-Aid for Young Scientists (B)